BRAF V600E-mutant mCRC
The first and only treatment approved specifically for patients with BRAF V600E-mutant mCRC, who have received prior systemic therapy1,2
BRAFV600E-mutant mCRC
is an area of high unmet need
Patients with BRAFV600E-mutant mCRC have a poor prognosis2,3
- Overall survival is dramatically lower than for those with BRAF wild-type disease4
- Patients with BRAFV600E-mutant mCRC demonstrate a limited response to conventional chemotherapy-based regimens2
Mutations are common
in patients with mCRC2,5
in patients with mCRC2,5


a predictive marker
